 | • レポートコード：MRC2303G027 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、137ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の急性虚血発作診断市場規模が、2021年には2,348.58百万ドルに及び、予測期間中、CAGR 6.86％で増加すると推測されています。本書では、急性虚血発作診断の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、診断種類別（CT、MRI、頸動脈超音波、脳血管撮影、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Fujifilm Holdings Corporation、Samsung Electronics Co. Ltd、GE Healthcare、Nihon Kohden Corporation、Canon Medical Systems Corporation、Koninklijke Philips NVなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の急性虚血発作診断市場規模：診断種類別 - CTの市場規模 - MRIの市場規模 - 頸動脈超音波の市場規模 - 脳血管撮影の市場規模 - その他急性虚血発作診断の市場規模 ・世界の急性虚血発作診断市場規模：地域別 - 北米の急性虚血発作診断市場規模 アメリカの急性虚血発作診断市場規模 カナダの急性虚血発作診断市場規模 メキシコの急性虚血発作診断市場規模 … - ヨーロッパの急性虚血発作診断市場規模 ドイツの急性虚血発作診断市場規模 イギリスの急性虚血発作診断市場規模 フランスの急性虚血発作診断市場規模 … - アジア太平洋の急性虚血発作診断市場規模 中国の急性虚血発作診断市場規模 日本の急性虚血発作診断市場規模 インドの急性虚血発作診断市場規模 … - 南米/中東の急性虚血発作診断市場規模 ブラジルの急性虚血発作診断市場規模 アルゼンチンの急性虚血発作診断市場規模 サウジアラビアの急性虚血発作診断市場規模 … ・競争状況 ・市場機会・将来動向 |
The acute ischemic stroke diagnostics market is expected to register a CAGR of 6.86% during the forecast period and market size of USD 2,348.58 million in 2021.
The acute ischemic stroke diagnostics market is anticipated to have been significantly impacted by the outbreak of the COVID-19 pandemic, as most of the medical procedures were deferred to contain the spread of SARS-Cov2 viral transmission. According to the research article published in the Journal of Cardiothoracic Surgery in March 2021 by Julie Sanders, cardiac surgery reduced by 50–75% during the pandemic, with a 50% reduction in dedicated cardiac theater rooms and ICU beds in the United Kingdom. Additionally, as per the study results published in the journal of Annals of Thoracic Surgery, in July 2021, “The Effect of COVID-19 on Adult Cardiac Surgery in the United States in 717 103 Patients,” an estimated 53% decrease in the total cardiac surgery volume was observed in the United States in 2020 as compared to 2019, which was majorly attributed to the impact of COVID-19 pandemic.
The rising prevalence of acute ischemic stroke cases is driving the global demand for both diagnostic and surgical procedures in acute stroke treatment. Cardiovascular diseases (CVDs) are the leading cause of death worldwide, according to World Health Organization (WHO) statistics for June 2021. It also states that an estimated 17.9 million people died from cardiovascular diseases in 2019, accounting for 32% of all global deaths. 85 % of these deaths were caused by a heart attack or a stroke. According to the same source, non-communicable diseases are responsible for 17 million premature deaths (under the age of 70) in 2019, with cardiovascular diseases accounting for 38% of these deaths.
Technological advancements in surgical procedures, a rising aging population, increased demand for minimally invasive procedures, and growth in health care spending are the other major factors driving the growth of the global acute ischemic stroke diagnosis and treatment market. As per the data reported by the American College of Cardiology, in November 2020, approximately 1.2 million angioplasties were performed in a year in the United States. Moreover, the high accessibility and affordability of hospitals, as compared to the specialty clinics, are expected to attract a large patient population.
Excessive usage of medication for the treatment of ischemic stroke and the high cost of surgical procedures are hindering the growth of the market. However, stringent regulatory policies are expected to restrict the market growth.
Acute Ischemic Stroke Diagnosis Market Trends
The Computed Tomography (CT) Segment Led the Global Market Over the Forecast Period
Imaging studies are used in ischemic diagnosis for the detection of hemorrhage in acute stroke patients in order to assess the degree of brain injury and to identify the vascular lesion responsible for the ischemic deficit.
Some advanced CT and MRI technologies are able to distinguish between brain tissue that is irreversibly infarcted and that which is potentially salvageable, thereby allowing a better selection of patients likely to benefit from therapy.
Computed tomography is the leading diagnostics segment. The significant share of CT techniques is attributable to widespread access and speed of acquisition. In the hyperacute phase, a non-contrast CT (NCCT) scan is usually ordered to exclude or confirm hemorrhage; it is highly sensitive for this indication.
Additionally, new product launches and approval will push the market to grow to new heights. For instance, in May 2021, Philips Healthcare received approval from the United States Food and Drug Administration (USFDA) for the computed tomography system, the Spectral CT 7500, which uses intelligent software to deliver high-quality spectral images on every scan 100% of the time without the need for special protocols.
Thus, the aforementioned factors such as technological advancement and product launch are expected to boost the segment over the forecast period.
North America Holds the Large Market Share in the Market Over the Forecast Period
North America dominates the market for acute ischemic stroke diagnosis devices, and it is estimated to continue its stronghold in the market, owing to favorable government initiatives, technological innovations, and increasing demand for ischemic stroke products. Furthermore, key players operating in the market are focusing on the adoption of inorganic growth strategies such as acquisition and agreements in order to expand their product portfolio and presence in the global acute ischemic stroke (AIS) market. For instance, in November 2020, AstraZeneca, a global, science-led biopharmaceutical company, announced the launch of the product Brilinta (an oral, reversible, direct-acting P2Y12 receptor antagonist), which is used to reduce the risk of stroke, a leading global cause of disability and death, in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).
Additionally, the increasing prevalence of stroke across North America drives market growth. According to the American Heart Association 2022, in the United States in 2019, cardiovascular disease (CVD) was recognized as the underlying cause of mortality, accounting for 874,613 fatalities. Additionally, according to the article published in the American Heart Association Journal in May 2021, by Dawn O. Kleindorfer, in the United States, 795 000 people have a stroke each year, with 87% (690 000) being ischemic and 185 000 being recurrent. Each year, over 240,000 people suffer from a transient ischemic attack (TIA). Thus, the increasing prevalence of cardiovascular diseases and stroke in the country is expected to boost the acute ischemic stroke diagnosis market.
Thus, the aforementioned factors are expected to boost the market over the forecast period in North America.
Acute Ischemic Stroke Diagnosis Market Competitor Analysis
The leading vendors of acute ischemic stroke diagnosis products are expanding their operations in Asian countries (India, China, Japan, and South Korea), as these economies hold immense potential for acute ischemic stroke diagnosis. Major players operating in the global acute ischemic stroke diagnosis market include Fujifilm Holdings Corporation, Samsung Electronics Co. Ltd, GE Healthcare, Nihon, Kohden Corporation, Canon Medical Systems Corporation, and Koninklijke Philips NV.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 The Rising Number of Acute Stroke Patients
4.2.2 Technological Innovations in Diagnostic and Surgical Devices
4.3 Market Restraints
4.3.1 Alternative Treatments and High Costs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 Diagnostic Type
5.1.1 Computed Tomography
5.1.2 Magnetic Resonance Imaging
5.1.3 Carotid Ultrasound
5.1.4 Cerebral Angiography
5.1.5 Electrocardiography
5.1.6 Echocardiography
5.1.7 Other Diagnostic Types
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Fujifilm Holdings Corporation
6.1.2 Samsung Electronics Co. Ltd
6.1.3 GE Healthcare
6.1.4 Nihon Kohden Corporation
6.1.5 Canon Medical Systems Corporation
6.1.6 Koninklijke Philips NV
6.1.7 Siemens Healthineers AG
6.1.8 Mindray Medical International Limited
6.1.9 Nanavati Super Speciality Hospital
6.1.10 F. Hoffmann-La Roche AG
6.1.11 Boehringer Ingelheim
6.1.12 Global Diagnostics (Integral Diagnostics Group)
6.1.13 Memorial Health System (Memorial Medical Center)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
